<DOC>
	<DOCNO>NCT01903291</DOCNO>
	<brief_summary>The primary objective study estimate annualized relapse rate ( ARR ) 12-month period patient relapse form multiple sclerosis ( MS ) treat dimethyl fumarate ( DMF ) suboptimal response glatiramer acetate ( GA ) . The secondary objective study study population ass impact DMF 12-month period patient-reported outcome ( PROs ) health economic-related outcome evaluate additional clinical outcome Month 12 .</brief_summary>
	<brief_title>Effectiveness DMF Its Impact PROs Suboptimal GA Responders With RMS</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Dimethyl Fumarate</mesh_term>
	<criteria>Key Have ability understand purpose risk study provide sign date informed consent authorization use Protected Health Information accordance national local patient privacy regulation . Have ability read understand write English . Have access internet able complete online assessment computer Have relapse form Multiple Sclerosis satisfy approve therapeutic indication dimethyl fumarate ( DMF ) per United States Prescribing Information ( USPI ) . Are treat relapse form multiple sclerosis ( MS ) glatiramer acetate ( GA ) , per Prescribing Physician , suboptimal response ( e.g. , suboptimal efficacy , intolerance , poor adherence ) GA stop treatment GA relapsing form MS result suboptimal response within 30 day enrollment . Have decide initiate treatment dimethyl fumarate ( DMF ) routine clinical care . The decision initiate treatment DMF must precede enrollment . Have complete blood count ( CBC ) available within 6 month initiation treatment dimethyl fumarate ( DMF ) . Key Are unwilling unable comply study requirement , , deem unsuitable study participation discretion Prescribing Physician . Have major comorbid condition would preclude participation study determine Prescribing Physician . Have history malignancy . ( Patients basal cell carcinoma completely excise prior study entry remain eligible . ) Have history and/or current serious infection . Are pregnant breastfeeding , plan become pregnant breastfeed . Are receive concomitant disease modify therapy glatiramer acetate ( GA ) initiate treatment new diseasemodifying therapy since discontinuation glatiramer acetate ( GA ) . Are currently enrol clinical study , exception dimethyl fumarate ( DMF ) Pregnancy Registry . Have receive prior treatment dimethyl fumarate ( DMF ) . NOTE : Other protocol define Inclusion/Exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>